124 related articles for article (PubMed ID: 15487038)
1. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.
Beenhouwer D; Wallis R; Broder M; Furst DE
J Rheumatol; 2004 Oct; 31(10):1888-92. PubMed ID: 15487038
[No Abstract] [Full Text] [Related]
2. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
3. [New treatments for rheumatoid arthritis].
Girault V; Flipo RM
Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
[No Abstract] [Full Text] [Related]
4. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
5. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
Fleischmann R; Shealy D
Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
[No Abstract] [Full Text] [Related]
6. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
Anderson P; Louie J; Lau A; Broder M
Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
[No Abstract] [Full Text] [Related]
7. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
8. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
[No Abstract] [Full Text] [Related]
9. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
Wollheim FA
Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
[No Abstract] [Full Text] [Related]
10. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
[No Abstract] [Full Text] [Related]
11. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
12. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
Jit M; Henderson B; Stevens M; Seymour RM
Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
14. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
[No Abstract] [Full Text] [Related]
15. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
Kavanaugh A; Cohen S; Cush JJ
J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
[No Abstract] [Full Text] [Related]
16. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Okamoto H
N Engl J Med; 2006 Nov; 355(19):2047; author reply 2048. PubMed ID: 17099950
[No Abstract] [Full Text] [Related]
17. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Roos JC; Ostor AJ
N Engl J Med; 2006 Nov; 355(19):2046-7; author reply 2048. PubMed ID: 17093259
[No Abstract] [Full Text] [Related]
18. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
Matsumoto T; Tanaka T; Kawase I
N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
[No Abstract] [Full Text] [Related]
19. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for patients with rheumatoid arthritis.
Oliver S; Mooney J
Prof Nurse; 2002 Aug; 17(12):716-20. PubMed ID: 12229045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
